Related Experiment Videos
New agents in the treatment of primary brain tumors
1University of Kansas Medical Center, Kansas City.
Abstract:
A review of single agent trials of cytotoxic agents in adults with high grade gliomas is presented. The rationale for testing these agents in patients with brain tumors was variable and is discussed. The criteria to evaluate responses were also variable ranging from subjective evaluation of clinical improvement with a stable radiographic assessment to the same objective response criteria utilized for solid tumors. Trials of agents specifically designed for brain tumors such as AZQ and spiromustine have been disappointing. There are encouraging results being seen in early trials of newer agents which await confirmation in larger trials but which hold promise for improving the disappointing results seen so far with chemotherapy in primary brain tumors.
Insights
Chemotherapy for high-grade gliomas in adults has shown disappointing results. Newer agents show promise in early trials, offering hope for improved outcomes in brain tumor treatment.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
- Cancer research
Background:
- High-grade gliomas (HGGs) are aggressive brain tumors with poor prognoses.
- Chemotherapy is a key treatment modality, but efficacy in HGGs remains a challenge.
- Previous single-agent trials have yielded variable results and used inconsistent response criteria.
Purpose of the Study:
- To review single-agent cytotoxic trials in adult patients with high-grade gliomas.
- To discuss the rationale and response evaluation criteria used in these trials.
- To identify promising new agents for HGG treatment.
Main Methods:
- Systematic review of single-agent cytotoxic chemotherapy trials in adult HGGs.
- Analysis of the rationale for drug selection and tumor targeting.
- Evaluation of diverse response assessment criteria, including clinical, radiographic, and objective measures.
Main Results:
- Trials of agents specifically designed for brain tumors, such as AZQ and spiromustine, have been disappointing.
- Response evaluation criteria varied significantly across studies.
- Early trials of novel agents demonstrate encouraging preliminary results.
Conclusions:
- The development of effective chemotherapy for high-grade gliomas has been challenging.
- Inconsistent trial designs and response criteria complicate interpretation of past results.
- Emerging agents warrant further investigation in larger clinical trials for potential improvement in HGG treatment outcomes.